Voyageur Pharmaceuticals Ltd Issuance of 5th Product License for MultiXThick Radiographic Barium Contrast saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
- MultiXthin – For Flouroscopy market
Voyageur is prepared to test its newly-formulated products under GMP and HC guidelines and advance to clinical testing. Voyageur plans to ensure that it is creating the highest quality products prior to phase one marketing, sales and distribution to Canadian, USA and international markets.
Voyageur has begun the process to prepare applications for
FDA device registrations. Based on the new regulatory change of barium sulfate being designated as a device, versus its previous designation as a drug, Voyageur plans to move forward with a marketing and sales strategy for the US market.
Further to news releases dated April 13 and 23, 2021, the Company announces that it has closed the first tranche of a non-brokered private placement of common units ( Common Units ) and flow-through units ( Flow-Through Units ) (the Offering ). The Offering was a combination of (i) Common Units issued at a price of $0.15 per Common Unit and comprised of one (1)
Voyageur Pharmaceuticals Ltd. Issued 4th Health Canada License For Radiographic Barium Contrast Product
Brand Story
Voyageur Pharmaceuticals Ltd. (
TSX.V:VM) (
OTC:VYYRF) (the Company or Voyageur ) is pleased to announce that it has received approval from Health Canada (HC) for its product,
MultiXthin barium sulfate suspension. MultiXthin is specifically designed for single contrast radiographic examinations of the oesophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients.
Voyageur has built a suite of barium radiographic contrast media products for global sales and distribution. The following products have been licensed:
- SmoothX - For CT market